Vazquez-Carrera Manuel (Orcid ID: 0000-0001-7138-8207) ORAL ADMINISTRATION OF A NEW HRI ACTIVATOR AS A NEW STRATEGY TO IMPROVE HIGH-FAT-DIET-INDUCED GLUCOSE INTOLERANCE, HEPATIC STEATOSIS AND HYPERTRIGLYCERIDEMIA THROUGH FGF21

ORAL ADMINISTRATION OF A NEW HRI ACTIVATOR AS A NEW STRATEGY TO IMPROVE HIGH-FAT-DIET-INDUCED GLUCOSE INTOLERANCE, HEPATIC STEATOSIS AND HYPERTRIGLYCERIDEMIA THROUGH FGF21 Mohammad Zarei, Eugènia Pujol, Tania Quesada-López, Francesc Villarroya, Emma Barroso, Santiago Vázquez, Javier Pizarro-Delgado, Xavier Palomer, and Manuel Vázquez-Carrera Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, University of Barcelona, Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain, Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, Pediatric Research Institute-Hospital Sant Joan de Déu, Department of Biochemistry and Molecular Biology and IBUB, University of Barcelona, Spanish Biomedical Research Center in Physiopathology of Obesity and Nutrition (CIBEROBN)-Instituto de Salud Carlos III